Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Net Cash Flow: 2019-2025

Historic Net Cash Flow for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$14.5 million.

  • Allogene Therapeutics' Net Cash Flow rose 87.84% to -$14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.4 million, marking a year-over-year increase of 25.45%. This contributed to the annual value of -$7.9 million for FY2024, which is 137.35% down from last year.
  • Per Allogene Therapeutics' latest filing, its Net Cash Flow stood at -$14.5 million for Q3 2025, which was down 246.98% from $9.9 million recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Net Cash Flow high stood at $119.6 million for Q2 2024, and its period low was -$119.4 million during Q3 2024.
  • For the 3-year period, Allogene Therapeutics' Net Cash Flow averaged around -$2.2 million, with its median value being $9.9 million (2025).
  • Within the past 5 years, the most significant YoY rise in Allogene Therapeutics' Net Cash Flow was 288.89% (2023), while the steepest drop was 294.36% (2023).
  • Over the past 5 years, Allogene Therapeutics' Net Cash Flow (Quarterly) stood at -$15.9 million in 2021, then rose by 21.50% to -$12.5 million in 2022, then skyrocketed by 211.69% to $13.9 million in 2023, then spiked by 72.40% to $24.0 million in 2024, then skyrocketed by 87.84% to -$14.5 million in 2025.
  • Its last three reported values are -$14.5 million in Q3 2025, $9.9 million for Q2 2025, and -$32.8 million during Q1 2025.